Psychiatry Research Case Reports
May 22, 2026
Albert Yeung, Huiqiong Deng, Wendy Feng et al.
Background Posttraumatic stress disorder (PTSD) remains a challenging condition to treat. Nonpsychedelic pharmacotherapies have modest efficacy, and trauma-focused therapies such as Cognitive Behavioral Therapy (CBT) and Eye Movement Desensitization and Reprocessing (EMDR) demonstrate higher response rates than medications, yet they suffer from high dropout rates (25–35%) and limited...
Scientific Reports
May 21, 2026
Amy Z Wang, Carissa W Tomas, Sarah Stevens et al.
Research has identified functional connectivity abnormalities in the default mode network (DMN), a functional brain network theorized to be involved in self-referential processes, among trauma survivors. Event centrality (EC) is an important cognitive component of posttrauma stress disorder (PTSD) development that heavily involves self-referential processing and autobiographical memory....
Current Treatment Options in Psychiatry
May 14, 2026
Deidre A. Marsh, Edwin Bacalso
Abstract Psychedelic-assisted therapy (PAT) is a novel and promising form of treatment for posttraumatic stress disorder (PTSD). However, clinicians may experience challenges in interpreting the existing evidence for PAT to make informed decisions about treatment recommendations and selection with their patients. Prior commentators have noted the hype surrounding public discussions of PAT. This...
Behavioral sciences (Basel, Switzerland)
May 14, 2026
Fabiola Raffone, Carlo Ignazio Cattaneo, Enrico Pessina et al.
Trauma-related autobiographical memories can manifest as involuntary, vivid, emotionally charged intrusions that perpetuate avoidance, negative emotions, and functional impairment. While these memories are central to post-traumatic stress disorder (PTSD), they also occur across diagnoses and are often reported in depressive disorders, including treatment-resistant depression (TRD). Although...
ACS Chemical Neuroscience
May 6, 2026
Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...
Sleep
May 1, 2026
Westley Youngren, Victoria West Staples, Emma Angle et al.
Abstract Introduction Targeted Dream Incubation (TDI) is the process of giving an individual auditory cues (i.e., “think of a tree”) while they are falling asleep, with the goal of shaping dream content (into something such as a tree). Recent research has demonstrated TDI may be able to increase dream self-efficacy (DSE) and influence other mental health outcomes. Thus, our study explored how...
Sleep
May 1, 2026
Holland Doise, A. Gonzalez Quesada, Garrett Baber et al.
Abstract Introduction Nightmares are associated with more severe posttraumatic stress disorder (PTSD). The advent of large language models (LLM) offers unique advantages to efficiently code affective dream content over human methods, which can be resource intensive and prone to error. This study tested whether dream affect (DA), measured via self-report, human-rated narrative coding, and LLM...
Cureus
May 1, 2026
Ngo Cheung
Trauma-related dissociation can present with derealisation, depersonalisation, abrupt lapses in awareness, memory gaps, and fugue-like states, and it may be difficult to treat with standard approaches alone. Glutamatergic interventions have been proposed as neuroplasticity-focused strategies because N-methyl-D-aspartate (NMDA) receptor antagonism and downstream...
JAMA Psychiatry
May 1, 2026
Amanda Jones, Jennifer Warner-Schmidt, Hannah Kwak et al.
6 citations
The phase 2 data presented here support the development of TSND-201 for posttraumatic stress disorder (PTSD), a disorder for which there is a significant unmet need for rapid-acting and effective treatments. TSND-201 (methylone) is a highly selective, rapid-acting neuroplastogen that releases serotonin, norepinephrine, and dopamine without direct activity at 5-hydroxytryptamine (5-HT) 2A...